Side-by-side · Research reference

TesamorelinvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship27/68 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Tesamorelin

GHRH Analogue · FDA-Approved

2 mgDaily doseEGRIFTA® (tesamorelin for inje 2010

15–20%VAT reductionFalutz 2010

~26 minHalf-lifeEGRIFTA® (tesamorelin for inje 2010

SQ · Abdomen · Once Daily

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Tesamorelin

Vilon

Primary target

Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010

Immune cell differentiation pathways, chromatin modification

Pathway

GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Yes — physiological pulsatility preserved

Unknown — no HPA/HPG axis data

Origin

Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

~50% after 26 wks (non-neutralising in most)Sévigny 2018

—

02Dosage Protocols

Parameter

Tesamorelin

Vilon

Standard dose

2 mg / dayEGRIFTA® (tesamorelin for inje 2010

FDA-approved protocol.

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Once daily (morning or pre-sleep)

Aligns with natural GH pulse.

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

1 mg / dayFalutz 2010

1 mg still produces significant IGF-1 elevation.

—

Evidence basis

RCT / FDA-approvedFalutz 2007 Falutz 2010

Mouse / in vitro only

Duration

12–52 weeks

VAT returns within months of stopping.

Not characterised in humans

Reconstitution

Sterile water per labeling

Preserved at 2–8 °C after reconstitution.

—

Timing

Empty stomach, pre-sleep preferred

—

Half-life

~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010

Modified vs native GHRH (7 min t½).

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

03Metabolic / Fat Loss Evidence

Parameter

Tesamorelin

Vilon

Primary fat target

Visceral adipose tissue (VAT) — abdominal

—

Quantified reduction

15–20% VAT ↓Falutz 2010

By CT at 26 weeks (Falutz et al., NEJM).

—

IGF-1 impact

+66 ng/mL (2 mg dose) · +81% mean elevationFalutz 2007

—

Effect on lean mass

Modest lean mass preservation / slight increase

—

Insulin sensitivity

Neutral to slight impairment (monitor HbA1c)Clarke 2018

—

Triglycerides

Significant TG reduction noted in Phase 3Falutz 2010

—

Glucose metabolism

Generally neutral; 4.5% HbA1c elevation riskClarke 2018

—

Effect reversibility

VAT returns within months of stopping

—

Key publication

Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007 Falutz 2010 EGRIFTA® (tesamorelin for inje 2010

—

04Side Effects & Safety

Parameter

Tesamorelin

Vilon

Injection site reaction

Erythema, pruritus, redness (common)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)

—

Glucose intolerance

HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018

—

IGF-1 elevation

Dose-dependent; supraphysiological levels = discontinue

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010

—

Antibody formation

~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018

Not reported; dipeptides generally low immunogenicity

GI symptoms

Nausea, diarrhea (mild, transient)

—

Pregnancy / OB

ContraindicatedEGRIFTA® (tesamorelin for inje 2010

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Tesamorelin

·Active malignancy or history of treated cancer
·Pregnancy
·Hypersensitivity to tesamorelin or mannitol
·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Tesamorelin

·Untreated diabetes (monitor HbA1c)
·Severe carpal tunnel syndrome
·Acute critical illness

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Tesamorelin

Vilon

1. Reconstitution

Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.

—

06Stack Synergy

Tesamorelin

+ Ipamorelin

Strong

View Ipamorelin →

Tesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.

Tesamorelin: 2 mg SQ · evening
Ipamorelin: 200–300 mcg SQ · same injection
Frequency: Once daily, pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep quality

Raun 1998

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020